Keiretsu Forum Mid Atlantic
VC Fund
Atlantic Mine, United States
Keiretsu Forum Mid Atlantic is a VC fund in Atlantic Mine focused on Biotechnology and SaaS. Keiretsu Forum Mid-Atlantic offers you access to a wealth of international angel funding opportunities, vetted by business experts with local first hand knowledge of every investment.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Keiretsu Forum Mid Atlantic invests in
Stages Keiretsu Forum Mid Atlantic invests in
Countries Keiretsu Forum Mid Atlantic invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eleanor Haas
|
|||
Chuck Carter
|
|||
Harvey Homan
|
|||
Vincent Leusner
|
Investment Focus
Industry
- Biotechnology 5 (38%)
- SaaS 3 (23%)
- Health Care 3 (23%)
- Pharmaceutical 3 (23%)
- Medical 2 (15%)
Stage
- Series A 5 (38%)
- Seed 2 (15%)
- Series B 2 (15%)
- Funding Round 2 (15%)
- Venture - Series Unknown 1 (8%)
Country
- United States 10 (77%)
- Canada 1 (8%)
- Israel 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Eleanor Haas
Director
|
Director | Total investments: 0 | Find email | |
|
Chuck Carter
President, Philadelphia & Pittsburgh Chapters
|
President, Philadelphia & Pittsburgh Chapters | Total investments: 0 | Find email | |
|
Harvey Homan
President, North Jersey Chapter
|
President, North Jersey Chapter | Total investments: 0 | Find email | |
Howard Lubert
Co-founder
|
Co-founder | Total investments: 2 | Find email | |
|
Vincent Leusner
Co-Founder & Area Vice President
|
Co-Founder & Area Vice President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aline
|
Aline develops software that digitizes legal contracts and builds smart automated workflows for contracts. | $4.5M / Seed / Jul 01, 2025 | |
Bow Wow Labs
|
Bow Wow Labs is an e-commerce website that offers natural chews, nutritious treats, oral care, and starter kits for pets. | Venture - Series Unknown / Jan 01, 2024 | |
FEMSelect
|
FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform. It is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. Using EnPlace takes approximately 30 minutes. The patented delivery system enables the precise guidance, insertion, anddeployment of the anchor unit. The anchor is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization.FEMSelect was founded in 2012 and is headquartered in Modi’in, Israel. | $9M / Series B / Oct 19, 2022 | |
iQure Pharma
|
iQure Pharma is a global biotech company created by entrepreneurs and former pharma managers that focuses on the development of new therapeutics. | $600K / Series A / Aug 30, 2022 | |
Soteria Battery Innovation Group
|
Soteria is revolutionizing lithium-Ion battery safety to enable inherently safe batteries everywhere. Soteria’s technology acts as an internal fuse within the battery to prevent ignition events. It aims to ensure that these materials are available to every battery manufacturer with local production from a broad supply base so that every device -whether a hearing aid or an electric bus - can have a battery that is virtually impossible to self-ignite. It was founded in 2017 and is headquartered in Greenville, South Carolina. | $3M / Series A / Nov 06, 2020 | |
ExpressCells
|
ExpressCells is a biotechnology company that uses genetic engineering to create custom cell lines for biological research and drug discovery. The company's primary focus is on creating research tools that will speed drug discovery and provide better disease models for basic researchers.ExpressCells was established by Oscar Perez-Leal andMatt Handel in 2018 and is headquartered in Philadelphia, Pennsylvania. | $1.2M / Series A / Jul 01, 2019 | |
Astarte Medical
|
Astarte Medical is a clinical intelligence company using software and predictive analytics to improve outcomes for children with medical complexity. Astarte Medical supports standardized care protocols, care planning and decision-making in acute, complex care settings with a suite of digital tools and diagnostics designed to optimize care andoutcomes for vulnerable patient populations when there is great opportunity to impact long-term health. | $5M / Series A / May 07, 2019 | |
|
Astarte Medical
|
Astarte Medical is a clinical intelligence company using software and predictive analytics to improve outcomes for children with medical complexity. Astarte Medical supports standardized care protocols, care planning and decision-making in acute, complex care settings with a suite of digital tools and diagnostics designed to optimize care andoutcomes for vulnerable patient populations when there is great opportunity to impact long-term health. | $5M / Series A / Mar 07, 2019 | |
Laurent Pharmaceuticals
|
Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical-stage, orally-active drug candidate. The company has a clinical-stage drug development program (LAU-7b) that addresses the compromised immune-inflammatory response in Cystic Fibrosis (CF), a critical but still enigmatic pathogenic pathway leading to pulmonaryinsufficiency in CF patients.Laurent Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | Oct 25, 2018 | |
Phytonix
|
Phytonix Corporation is an industrial biotechnology company producing sustainable chemicals directly from carbon dioxide. The company’s patented process employs cyanobacteria, and it is a professional in bio-safe, direct solar chemicals and fuel production utilizing carbon dioxide as the sole feedstock and energy from the sun.Phytonix Corporationand its partners utilize a collaborative and distributed business model based upon circular economy principles, to produce a variety of renewable chemicals and biofuel from carbon dioxide, sunlight, and water via patented photobiological and genomics technology. It also produces biobutanol and biopentanol, industrial chemicals, and potential fuels to replace gasoline.Phytonix Corporation’s first product in its pipeline, n-butanol, can be used for a broad array of fuels and chemicals, including jet fuels, bio-based plastics, and synthetic rubber. Its n-butanol production process is a replacement for the fossil-based, carbon-intensive process currently used by the world’s largest chemical companies. The company seeks to eliminate the need for biomass, such as food or other crops, in both biochemical and biofuel production.Phytonix Corporation has developed engineered cyanobacterial species that secrete n-butanol in a significantly carbon-negative, photosynthetic process. The company estimates that the production cost of its biobutanol will be 1.35 U.S. dollars per gallon. It was founded in 2009 by Bruce Dannenberg and is headquartered in Asheville, North Carolina. | Oct 18, 2018 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Keiretsu Forum Mid Atlantic invest in?
Keiretsu Forum Mid Atlantic invests primarily in Biotechnology, SaaS and Health Care startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Keiretsu Forum Mid Atlantic?
Public channels for Keiretsu Forum Mid Atlantic include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Keiretsu Forum Mid Atlantic?
The team at Keiretsu Forum Mid Atlantic includes Eleanor Haas (Director), Chuck Carter (President, Philadelphia & Pittsburgh Chapters) and Harvey Homan (President, North Jersey Chapter). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
